SCF PRECLINICAL DEVELOPMENT BLUEPRINT
AMX-202
FDA-Aligned IND-Enabling Development Program for Hepatic Encephalopathy
Document Code: SCF-AMMONEX-HE-PRECL-0001
Candidate: AMX-202
Program: PROJECT AMMONEX-HE
Development Stage: Preclinical Candidate Validation → IND-Enabling Package
Regulatory Objective: Generate sufficient pharmacology, ADME, toxicology, CMC, and translational biomarker data to support an Investigational New Drug (IND) application and First-In-Human (FIH) study initiation.
SECTION I — PRECLINICAL DEVELOPMENT STRATEGY
Primary Hypothesis
AMX-202 reduces hyperammonemia and hepatic encephalopathy progression through coordinated modulation of:
- Gut ammonia production
- Hepatic nitrogen metabolism
- Gut barrier integrity
- Neuroinflammatory signaling
- Astrocyte stress pathways
SECTION II — TARGET PRODUCT PROFILE (PRECLINICAL)
Parameter | Target |
Route | Oral |
Dosing | Once Daily |
Primary Effect | Plasma ammonia reduction |
Secondary Effect | Neurocognitive improvement |
Safety Goal | No hepatotoxicity or neurotoxicity |
Population | Cirrhosis-associated HE |
SECTION III — DISCOVERY VALIDATION CASCADE
WORKSTREAM A
Molecular Pharmacology
Objective
Demonstrate target engagement.
Assays
Assay | Endpoint |
Urease inhibition | IC50 |
TLR4 activation | Signal reduction |
NF-κB reporter assay | Pathway suppression |
NLRP3 activation assay | Inflammasome inhibition |
Cytokine profiling | TNF-α, IL-6 reduction |
Go Criterion
≥50% activity at therapeutically relevant concentrations.
WORKSTREAM B
Hepatic Nitrogen Metabolism
Objective
Demonstrate modulation of ammonia handling.
Models
Model | Endpoint |
Primary hepatocytes | Urea production |
HepG2 cells | Nitrogen metabolism markers |
Liver organoids | Urea-cycle activity |
Biomarkers
- Urea
- Citrulline
- Ornithine
- Arginine
- Glutamine
WORKSTREAM C
Gut Barrier Restoration
Objective
Demonstrate restoration of epithelial integrity.
Models
Model | Endpoint |
Caco-2 monolayer | TEER |
Intestinal organoids | Barrier integrity |
LPS challenge | Inflammatory response |
Biomarkers
- Zonulin
- Claudin-1
- Occludin
- LPS
WORKSTREAM D
Astrocyte Protection
Objective
Reduce ammonia-induced astrocyte injury.
Models
Model | Endpoint |
Human astrocytes | Cell swelling |
Hyperammonemia model | Glutamine accumulation |
Mitochondrial assays | ATP preservation |
Biomarkers
- GFAP
- Glutamine
- ROS
- ATP
SECTION IV — ADME PROGRAM
Absorption
Studies
- Solubility
- Permeability (Caco-2)
- Dissolution profiling
Target
Orally bioavailable formulation.
Distribution
Studies
- Tissue distribution
- Portal vein exposure
- Liver concentration
Target
Gut–portal–liver enrichment.
Metabolism
Studies
- Human liver microsomes
- Hepatocyte stability
- CYP interaction panel
Target
Minimal CYP liability.
Excretion
Studies
- Renal elimination
- Biliary elimination
- Mass balance
SECTION V — PK/PD MODELING
Primary PK Endpoints
Parameter | Goal |
Cmax | Defined |
Tmax | Defined |
AUC | Defined |
t½ | 12–24 hr |
Bioavailability | Acceptable |
PD Endpoints
Endpoint | Goal |
Ammonia | Reduction |
Glutamine | Reduction |
IL-6 | Reduction |
TNF-α | Reduction |
SECTION VI — ANIMAL MODEL STRATEGY
Model 1
Hyperammonemia Rat
Purpose:
Proof-of-concept.
Endpoints:
- Plasma ammonia
- Cognitive performance
- Survival
Model 2
Portal-Systemic Shunt Rat
Purpose:
HE simulation.
Endpoints:
- Neurological score
- EEG
- Ammonia burden
Model 3
Bile Duct Ligation Model
Purpose:
Cirrhosis-associated HE.
Endpoints:
- Liver injury
- Neuroinflammation
- Plasma ammonia
Model 4
Carbon Tetrachloride Cirrhosis Model
Purpose:
Chronic disease validation.
Endpoints:
- Fibrosis
- Ammonia
- Cognitive function
SECTION VII — GLP TOXICOLOGY PROGRAM
Safety Pharmacology Core Battery
Cardiovascular
- Blood pressure
- Heart rate
- ECG
Respiratory
- Respiratory rate
- Oxygen saturation
CNS
- Functional observational battery
- Motor activity
- Behavioral analysis
Repeat-Dose Toxicology
Rodent
28-day study
Non-Rodent
28-day study
Assess:
- Clinical pathology
- Histopathology
- Organ weights
Genetic Toxicology
Required Studies
- Ames test
- In vitro micronucleus assay
- Chromosomal aberration assay
FDA-aligned IND-enabling toxicology package.
SECTION VIII — CMC DEVELOPMENT ROADMAP
API Development
Requirements
- Identity
- Purity
- Potency
- Stability
Analytical Methods
Test | Purpose |
HPLC | Purity |
LC-MS | Identity |
Dissolution | Release profile |
Stability | Shelf life |
Manufacturing
Goal
GMP-compatible process suitable for:
- IND
- Phase I
- Phase II
SECTION IX — TRANSLATIONAL BIOMARKER PROGRAM
Primary Biomarkers
Biomarker | Role |
Plasma ammonia | Primary PD marker |
Urea | Nitrogen metabolism |
Glutamine | Neurotoxicity marker |
Secondary Biomarkers
Biomarker | Role |
IL-6 | Inflammation |
TNF-α | Neuroimmune activity |
CRP | Systemic inflammation |
LPS | Gut barrier dysfunction |
Exploratory Biomarkers
Biomarker | Role |
EEG | Neural function |
Cognitive testing | Clinical translation |
Neurofilament light chain | Neural injury |
SECTION X — PRE-IND PACKAGE
FDA Meeting Objectives
Obtain Feedback On
- Pharmacology strategy
- Animal model selection
- Toxicology package
- Biomarker plan
- FIH protocol framework
SECTION XI — GO / NO-GO MATRIX
GO
Efficacy
- ≥30% ammonia reduction
- Significant neurocognitive improvement
- Biomarker response demonstrated
Safety
- Acceptable therapeutic index
- No major target-organ toxicity
PK
- Once-daily exposure feasible
NO-GO
- Significant hepatotoxicity
- Poor oral PK
- No ammonia reduction
- Unacceptable safety margin
SECTION XII — IND-ENABLING TIMELINE
Stage 1
Mechanistic Validation
Outputs:
- Target engagement
- MoA confirmation
Stage 2
Proof-of-Concept Efficacy
Outputs:
- Dose-response
- PK/PD relationship
Stage 3
GLP Safety Package
Outputs:
- NOAEL
- Toxicokinetics
- Safety pharmacology
Stage 4
IND Assembly
Modules:
- Nonclinical
- CMC
- Clinical Protocol
Aligned with FDA IND requirements and clinical development workflow architecture.
STRATEGIC NEXT COMMAND
IND PACKAGE
Outputs:
- Complete IND dossier structure
- Module 3 CMC blueprint
- Module 4 Nonclinical blueprint
- Phase I protocol synopsis
- Investigator Brochure framework
- FDA pre-IND briefing package
- FIH starting dose rationale framework
MASTER REGISTRY INDEX
SCF-AMMONEX-HE-PRECL-0001 — Preclinical Development Blueprint
SCF-AMMONEX-HE-AMX202-0002 — Development Candidate Program
SCF-AMMONEX-HE-ADME-0003 — ADME & PK Framework
SCF-AMMONEX-HE-TOX-0004 — GLP Toxicology Program
SCF-AMMONEX-HE-CMC-0005 — CMC Development Roadmap
SCF-AMMONEX-HE-IND-0006 — IND-Enabling Strategy
SCF-AMMONEX-HE-FIH-0007 — First-In-Human Preparation Framework